ACCESSWIRE
09 Jun 2023, 03:55 GMT+10
CHICAGO, IL / ACCESSWIRE / June 8, 2023 / In a recent issue of Employee Benefit Plan Review, Bob Cohen and Don Nordstrom of ProManage, LLC explored what they labeled the 'warning signs' of Target Date Funds (TDFs) and what should be done about TDFs' limitations in the coming year.
In their article 'Warning Signs of Target Date Funds: What's Best for the Future,' published in January 2023, they explain that retirement assets invested in Target
Date Funds 'continue to grow (estimated at $1.8 trillion as of March 2022 per Morningstar) as defined contribution (DC) plan investors increasingly place their trust in these vehicles to be the solution to their future retirement needs. Despite this marketing success, it is long overdue to ask a few questions about the suitability and applicability of TDFs and their impact on retirement in the United States.'
They then cite a few general critiques of Target Date Funds including:
Their article also looks at TDFs' 'Inadequate Design' and 'Lack of Customization' including their assertion that customization is desirable due to the reality that retirement goals among individual plans and needs can vary greatly. As a result, '(R)etirees both present and future should utilize an investment strategy that can look at the big picture and accommodate their unique circumstances with a more personalized solution. Stock and bond performance in 2022 has revealed weaknesses in the investment thesis for TDFs. Target Date Funds do not fit the necessary profile for a successful retirement future.'
Publication Focus: Employee Benefit Plan Review ('EBPR') is a monthly national subscription-based journal published by Wolters Kluwer Law & Business that covers topics related to the management and administration of health and welfare benefits, pension benefits, employer communications, and compensation issues.
Author Bios: Co-author Bob Cohen is Chief Investment Officer of ProManage, LLC and co-author Don Nordstrom is a Senior Investment Analyst with the firm. The authors may be contacted at BCohen@promanageplan.com and dnordstrom@promanageplan.com
respectively. Web: https://promanageplan.com/
PR Contact: Ken Lizotte, ken@thoughtleading.com or 978-618-1164.
SOURCE: ProManage, LLC
Get a daily dose of San Francisco Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to San Francisco Star.
More InformationLos Angeles [US], September 21 (ANI): The release date for'American Fiction' has been changed. As per Variety, the makers have ...
San Francisco [USA], September 21 (ANI): Minor League Cricket (MiLC) announced on Thursday that the third season of America's most ...
Amman, Jordan - Iraq's Chaldean Catholic Cardinal, Louis Sako, is asking for more Vatican support to regain his title of ...
WASHINGTON - Warming relations between North Korea and Russia could last as long as the war in Ukraine continues, making ...
Riyadh wants a civilian atomic program but would also consider a military path, should Iran choose to take that routeIsrael ...
Dubai [UAE], September 21 (ANI): The International Cricket Council (ICC) confirmed Dallas, Florida and New York as the three USA ...
SEOUL, South Korea: Thousands of South Korean educators and school staff gathered in Seoul over the weekend to demand increased ...
WARSAW, Poland: As part of European Union (EU) sanctions imposed against Russia over its invasion of Ukraine, Poland banned all ...
MONTGOMERY, Alabama: Last week, Alabama's school chief, Superintendent Eric Mackey, said that under new reading benchmarks to move to fourth ...
WASHINGTON D.C.: Last week, the Federal Reserve said its losses surpassed the US$100 billion mark and will likely continue to ...
ARLINGTON, Virginia: This week, the U.S. State Department approved the potential sale of drone-related munitions and other systems to Canada ...
BETHESDA, Maryland: This week, the US National Institutes of Health (NIH) said that it started early-stage human trials on FluMos-v2, ...